Lifesci Capital Cuts Earnings Estimates for Sutro Biopharma

Sutro Biopharma, Inc. (NASDAQ:STRO) – Investment analysts at Lifesci Capital reduced their Q2 2026 earnings per share estimates for shares of Sutro Biopharma in a note issued to investors on Friday, May 15th. Lifesci Capital analyst C. Zhu now anticipates that the company will post earnings of ($1.55) per share for the quarter, down from their prior estimate of ($1.52). Lifesci Capital has a “Strong-Buy” rating on the stock. The consensus estimate for Sutro Biopharma’s current full-year earnings is ($9.04) per share. Lifesci Capital also issued estimates for Sutro Biopharma’s Q3 2026 earnings at ($1.40) EPS, Q4 2026 earnings at ($1.39) EPS, FY2026 earnings at ($7.76) EPS, Q1 2027 earnings at ($1.48) EPS, Q2 2027 earnings at ($1.54) EPS, Q3 2027 earnings at ($1.64) EPS, Q4 2027 earnings at ($1.47) EPS, FY2027 earnings at ($6.13) EPS and FY2028 earnings at ($6.35) EPS.

A number of other equities analysts have also weighed in on the company. Leerink Partners set a $43.00 price objective on Sutro Biopharma and gave the company an “outperform” rating in a research note on Friday. Weiss Ratings reiterated a “sell (d-)” rating on shares of Sutro Biopharma in a research note on Friday, May 8th. Wells Fargo & Company upgraded Sutro Biopharma from an “equal weight” rating to an “overweight” rating and lifted their price target for the company from $8.00 to $27.00 in a research note on Tuesday, March 24th. Wall Street Zen upgraded Sutro Biopharma from a “sell” rating to a “hold” rating in a research note on Saturday, March 28th. Finally, Truist Financial upgraded Sutro Biopharma to a “strong-buy” rating in a research note on Monday, May 4th. Three investment analysts have rated the stock with a Strong Buy rating, seven have given a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Buy” and a consensus price target of $48.25.

Sutro Biopharma Stock Performance

NASDAQ STRO opened at $34.48 on Tuesday. The stock has a 50-day simple moving average of $29.43 and a two-hundred day simple moving average of $18.50. The firm has a market capitalization of $571.33 million, a P/E ratio of -2.00 and a beta of 1.63. Sutro Biopharma has a fifty-two week low of $6.74 and a fifty-two week high of $43.85.

Sutro Biopharma (NASDAQ:STRO) last issued its quarterly earnings results on Thursday, May 14th. The company reported ($2.94) EPS for the quarter, missing analysts’ consensus estimates of ($2.74) by ($0.20). The business had revenue of $14.52 million during the quarter, compared to the consensus estimate of $8.89 million.

Institutional Investors Weigh In On Sutro Biopharma

Several large investors have recently bought and sold shares of STRO. Invesco Ltd. increased its stake in Sutro Biopharma by 137.8% during the 1st quarter. Invesco Ltd. now owns 92,139 shares of the company’s stock worth $60,000 after buying an additional 53,390 shares in the last quarter. AQR Capital Management LLC increased its stake in Sutro Biopharma by 1,052.8% during the 1st quarter. AQR Capital Management LLC now owns 1,320,917 shares of the company’s stock worth $859,000 after buying an additional 1,206,330 shares in the last quarter. Strs Ohio purchased a new stake in Sutro Biopharma during the 1st quarter worth approximately $99,000. Marshall Wace LLP purchased a new stake in Sutro Biopharma during the 2nd quarter worth approximately $166,000. Finally, Cerity Partners LLC increased its stake in Sutro Biopharma by 169.9% during the 2nd quarter. Cerity Partners LLC now owns 105,437 shares of the company’s stock worth $75,000 after buying an additional 66,372 shares in the last quarter. 96.99% of the stock is currently owned by hedge funds and other institutional investors.

About Sutro Biopharma

Sutro Biopharma, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of novel biologic drug candidates in the fields of oncology and immunology. The company leverages a proprietary cell-free protein synthesis platform, XpressCF™, to design and produce complex, multi-specific proteins that include antibody-drug conjugates, bispecific antibodies, and cytokine fusion proteins. This platform enables rapid generation and optimization of protein therapeutics that may not be feasible with traditional cell-based expression systems.

Founded in 2003 and headquartered in South San Francisco, California, Sutro Biopharma has built a pipeline of immuno-oncology candidates in various stages of preclinical and clinical development.